retatrutide type 2 diabetes trial results 2024 Phase demonstrate benefits of in obesity, 2 diabetes, NASH Retatrutide: Phase 3 Results (Up

Exploring potential drawbacks of Vitamin B12 shots

Trends in first-time prescribing First-time prescribing rates (first-time GLP-1 RA prescriptions per total prescriptions) in September 2025 are slightly decreased compared to June 2025 (-12.5%)

In Artemisia annua , the HD-Zip family proteins AaHD1 and AaHD8 directly activate the expression of MYB transcription factor AaTAR2 , which can activate the expression of artemisinin biosynthesis pathway enzyme genes ADS, CYP71AV1, DBR2 and ALDH1

For the treatment policy estimate, missing data were imputed using outcomes from participants who discontinued treatment but completed the week 26 visit [1]

Prescription Weight Loss Drugs Stigma The newest generation of weight loss drugs is changing the conversation about obesity

Increased expression of the immediate response gene, early growth response gene-1 (egr-1), was shown in Caco-2 cells in vitro (Tkalcevic et al., 2007)